Flag of the European Union EU Clinical Trials Register Help

Clinical trials for lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,346 result(s) found for: lymphoma. Displaying page 44 of 68.
    «« First « Previous 40  41  42  43  44  45  46  47  48  Next» Last»»
    EudraCT Number: 2009-014844-13 Sponsor Protocol Number: 50-2009 Start Date*: 2010-03-16
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantat...
    Medical condition: Treatment ot mantle cell lymphoma patients in first or second relapse or refractory disease. Patients should not be eligible for high dose chemotherapy with autologous or allogenous stem cell trans...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000734-21 Sponsor Protocol Number: FL05-1 Start Date*: 2005-09-13
    Sponsor Name:Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    Full Title: A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell Lymphoma
    Medical condition: Follicular Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000735-27 Sponsor Protocol Number: FIL_SGN01 Start Date*: 2013-07-23
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II study of SGN-35 (brentuximab vedotin) of patients with relapsed or refractory Primary mediastinal large B-cell lymphoma (PMLBCL).
    Medical condition: Relapsed or refractory Primary mediastinal large B-cell lymphoma (PMLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002140-22 Sponsor Protocol Number: Vitality Start Date*: 2020-11-02
    Sponsor Name:Lars møller Pedersen
    Full Title: Gonadal dysfunction in male long-term survivors of malignant lymphoma
    Medical condition: Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10043335 Testicular hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000591-97 Sponsor Protocol Number: CLSG-CNS-001 Start Date*: 2015-06-03
    Sponsor Name:Kooperativní lymfomová skupina, o.s.
    Full Title: Study evaluating relapses in central nervous system in patients with diffuse large B-cell lymphoma treated with chemotherapy with or without CNS prophylaxis. Multicentric, prospective randomized p...
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016136-12 Sponsor Protocol Number: RIMCEB-09 Start Date*: 2010-01-27
    Sponsor Name:Czech Lymphoma Research Organization s.r.o. (CLRO)
    Full Title: PET-RIMCEB: Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patients A phase III study A randomized, open-label trial comparing intensified immunochemothe...
    Medical condition: Prognosis of high-risk patients with diffuse large B-cell lymphoma is still less then optimal. According to revised Int. Prognostic Index, patients with 3-5 adverse prognostic factors have only abo...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003946-17 Sponsor Protocol Number: FIL_PTCL_BV Start Date*: 2015-09-15
    Sponsor Name:Fondazione Italiana Linfomi ONLUS
    Full Title: Phase II study on the role of brentuximab vedotin as single agent in the treatment of relapsed/refractory CD30 positive peripheral T cell lymphoma (PTCL) patients
    Medical condition: RELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T CELL LYMPHOMA (PTCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001676-11 Sponsor Protocol Number: FIL_MIRO Start Date*: 2014-10-28
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: "MIRO" study (Molecularly Oriented Immuno-radio-therapy): a multicenter phase II trail for the treatment on molecular basis of stage I / II Follicular Lymphoma with local radiotherapy with / witho...
    Medical condition: Stage I/II Follicular Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005375-15 Sponsor Protocol Number: MCL elderly Start Date*: 2006-04-21
    Sponsor Name:GELA
    Full Title: Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation
    Medical condition: Mantle cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004033-28 Sponsor Protocol Number: IPI-145-22 Start Date*: 2016-05-04
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects...
    Medical condition: Indolent Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002115-96 Sponsor Protocol Number: SCC215/P002900 Start Date*: 2021-04-23
    Sponsor Name:Klinikum Stuttgart, Landeshauptstadt Stuttgart gKAöR
    Full Title: Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial
    Medical condition: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is a rare disorder confined to the cerebral parenchyma, leptomeninges, eyes or spinal cord. It accounts for 4 to 6% of al...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004190-12 Sponsor Protocol Number: MK8808-003 Start Date*: 2013-03-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of MK-8808 versus MabThera™ in Patients with Advanced CD20-Positive Follicular Lymphoma.
    Medical condition: Previously untreated patients with CD20-positive follicular lymphoma, Grade 1, 2 or 3a according to the WHO 2008 classification system.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10059432 Follicular mixed small and large cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004604-20 Sponsor Protocol Number: MDX060-03 Start Date*: 2005-12-05
    Sponsor Name:Medarex, Inc.
    Full Title: An Open-Label, Two-Stage, Fixed-Dose, Multicenter Phase II Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease
    Medical condition: Relapsed or Refractory Hodgkin’s Disease
    Disease: Version SOC Term Classification Code Term Level
    5.0 10020266 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003468-19 Sponsor Protocol Number: ADVL0912 Start Date*: 2020-08-14
    Sponsor Name:Children’s Oncology Group
    Full Title: ADVL0912: A PHASE 1/2 STUDY OF PF02341066, AN ORAL SMALL MOLECULE INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE (ALK) AND C-MET, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID TUMORS AND ANAPLASTIC LARGE CEL...
    Medical condition: malignant solid tumors including Inflammatory myofibroblastic tumor (IMT) and anaplastic large-cell lymphoma (ALCL)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005069-60 Sponsor Protocol Number: P000798 Start Date*: 2015-05-26
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL
    Medical condition: Diffuse-large B cell lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005273-20 Sponsor Protocol Number: FIL-GALILEO Start Date*: 2016-02-11
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffus...
    Medical condition: Diffuse Large B-Cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003632-23 Sponsor Protocol Number: IC2019-02 Start Date*: 2020-06-17
    Sponsor Name:Institut Curie
    Full Title: LOC-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 with a newly diagnosed...
    Medical condition: Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10036685 Primary central nervous system lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005180-24 Sponsor Protocol Number: GS-US-312-0116 Start Date*: 2012-05-08
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000214-11 Sponsor Protocol Number: RG_11-225 Start Date*: 2013-06-18
    Sponsor Name:University of Birmingham
    Full Title: BREVITY: A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity
    Medical condition: Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020261 Hodgkin's disease NOS stage II LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020270 Hodgkin's disease stage III PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020269 Hodgkin's disease stage II PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061597 Hodgkin's disease stage IV PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020265 Hodgkin's disease NOS stage IV LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020264 Hodgkin's disease NOS stage III LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004469-32 Sponsor Protocol Number: CC-5013-CLL-001 Start Date*: 2007-02-23
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 1/2, MULTI-CENTER,OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF A STEPWISE DOSE-ESCALATION SCHEDULE OF LENALIDOMIDE MONOTHERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMP...
    Medical condition: For the treatment of relapsed or refractory B-CLL.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 40  41  42  43  44  45  46  47  48  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 18:44:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA